Basic studies into development of novel preventive and regenerative therapy for hepatocarcinogenic cirrhosis using bone marrow-derived cells having redox-regulatory capacity

点击翻译按钮获取中文摘要

We previously developed autologous bone marrow cell infusion (ABMi) therapy, which is a method of liver regeneration for liver cirrhotic patients using non-cultured autologous whole bone marrow cells, and reported the efficacy and safety of this approach. This ABMi therapy was officially approved as an "Advanced Medical Technology B" in Japan. We also reported that frequent bone marrow cell infusion contributed to suppressed tumor initiation during hepatocarcinogenesis. In these studies, we confirmed that hepatocytes co-cultured with bone marrow derived mesenchymal stem cells (MSCs) had lower levels of oxidative stress, and that cirrhotic mice treated with MSCs showed lower levels of liver fibrosis, higher serum antioxidant activity, and lower levels of hepatic malondialdehyde content. These results strongly indicate that cultured BMCs are a stem cell source in liver regeneration therapy for cirrhotic patients.